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Abstract: Tc-99m pertechnetate thyroid scintigraphy is used in the routine for the evaluation of residual tissue after total 
thyroidectomy operations in differentiating thyroid carcinoma. Tc-99m methoxy isobutyl isonitrile (Tc99m MIBI) was first 
developed as a myocardial perfusion agent and is also used for tumor imaging. Tc-99m MIBI is taken up by the 
functioning thyroid tissue and washed-out fast. We present a case of differentiated thyroid carcinoma where uptake out 
the thyroid bed was not detectable by Tc-99m pertechnetate thyroid scintigraphy but with Tc-99m MIBI scintigraphy in 
the postoperative period. 
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CASE REPORT 
Thyroid scintigraphy was performed to a 43-year-old 
female patient who underwent total thyroidectomy with 
papillary carcinoma and follicular variant. Postoperative 
thyroglobulin (Tg) was detected >300 ng/mL. Tc-99m 
pertechnetate thyroid scintigraphy showed very low 
suspicious activity uptake located on the right lateral 
neighbourhood of the thyroid bed (Figure 1). On neck 
ultrasonography (USG), no residual tissue was 
observed. However, in the middle cervical area on the 
right side, located lateral to the carotid artery, a lesion 
of 16X16X25mm with conglomerate appearance, 
including rough calcification foci and another 
heterogeneous lesion 10x8x10 mm in size containing 
cystic areas And than Tc-99m MIBI performed. On Tc-
99m MIBI thyroid scintigraphy, Tc-99m MIBI uptake 
was detected corresponding to the lesion defined by 
USG (Figure 2). Right lateral neck dissection was 
performed to the patient. Metastatic lymph nodes in 
size 3x2.5x1.7 cm were excised. 
DISCUSSION 
Tc-99m MIBI is a cationic-lipophilic isonitrile 
compound developed as a myocardial perfusion agent, 
is also used for tumor imaging [1, 2]. In this case, 
residual tumor tissue was not visible by Tc-99m 
pertechnetate scan but with Tc-99m MIBI, a 
nonspecific tumor agent. In differentiated thyroid 
 
 
*Address correspondence to this author at the Dışkapı Yıldırım Beyazıt Training 
and Research Hospital, Nuclear Medicine Department, Ankara, Turkey 06590; 
Tel: 90.535.5681066; Fax: +90.3123163499;  
E-mail: drderyaors@hotmail.com 
carcinomas, total thyroidectomy is generally followed 
by radioiodine therapy. The common suitability criteria 
for radioiodine therapy are existence of no or very 
small residual thyroid thyroid tissue and negative 
thyroglobulin and antithyroglobulin levels. High Tg 
 
Figure 1: Tc-99m pertechnetate thyroid scintigraphy showed 
very low suspicious activity uptake located on the right lateral 
neighbourhood of the thyroid bed. 
 
Figure 2: On Tc-99m MIBI thyroid scintigraphy, Tc-99m MIBI 
uptake was detected on the right lateral neighbourhood of the 
thyroid bed. 
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values in patients with differentiated thyroid carcinoma 
in the postoperative period is known as a poor 
prognostic factor and should be certainly further 
evaluated before radioiodine therapy [3]. Neck USG is 
now the most commonly used imaging tool in detection 
of regional lymph node involvement. In suspect of 
distant metastasis, 18F-Fluorodeoxyglucose positron 
emission tomography / computed tomography (FDG 
PET/CT) is now recommended [4]. However, as this 
high technology equipment may not be available widely 
and may not be practical to apply, Tc-99m MIBI seems 
to be a simple and cheap alternative to 18F-FDG for 
metabolic imaging in routine clinical practice. 
CONCLUSION 
Although Tc-99m MIBI scintigraphy is not routinely 
used for imaging of the thyroid gland. It should be 
considered that patients with abnormal Tg elevation in 
the postoperative period may be helpful if there is no 
significant residual tissue on the thyroid scintigraphy. 
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